Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1997-3-10
|
| pubmed:abstractText |
The efficacy and safety of sulbactam/cefoperazone (SBT/CPZ) were evaluated in 42 patients with respiratory tract infections, including pneumonia (29 patients) and lower respiratory tract infections (5 patients). Overall clinical efficacy rates (excellent + good) were 79% in pneumonia and 80% in respiratory tract infections in 34 patients evaluated for clinical efficacy. It was excellent that the clinical efficacy rate was 92% in mild and moderate pneumonia. Pathogens isolated from sputa were 31 strains, including 8 strains of Pseudomonas aeruginosa, 7 of Streptococcus pneumoniae, 3 of Staphylococcus aureus and 3 of Haemophilus influenzae. Since the isolates were eradicated in 18 strains, replaced in 3, unchanged in 2 and unknown in 8, the overall eradication rate was 91%. The eradication rates were 89% in beta-lactamase producing strains and 100% in beta-lactamase positive sputum, and excellent or good in 19 (83%) of 23 patients with beta-lactamase negative sputum. The eradication rate was 88% in 5 patients with beta-lactamase positive sputum. One patient experienced a moderate rash. Abnormal laboratory test values were observed in 10 patients (26.3%), but these abnormalities were mild and transient. These results suggested that SBT/CPZ was effective and safe for the treatment of respiratory tract infections caused by beta-lactamase producing as well as beta-lactamase non-producing bacteria.
|
| pubmed:language |
jpn
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0368-2781
|
| pubmed:author |
pubmed-author:AbeKK,
pubmed-author:DotsuYY,
pubmed-author:HaraKK,
pubmed-author:HashimotoAA,
pubmed-author:HirakataYY,
pubmed-author:HoriHH,
pubmed-author:ImamuraYY,
pubmed-author:InoueYY,
pubmed-author:IshiguroMM,
pubmed-author:KandaTT,
pubmed-author:KatsumataTT,
pubmed-author:KawamotoSS,
pubmed-author:KogaHH,
pubmed-author:KohnoSS,
pubmed-author:KusanoSS,
pubmed-author:MashimotoHH,
pubmed-author:MatsumotoYY,
pubmed-author:MorikawaNN,
pubmed-author:SasayamaKK,
pubmed-author:ShimoguchiKK,
pubmed-author:SugiyamaHH,
pubmed-author:TanakaHH,
pubmed-author:TanakaKK,
pubmed-author:TomonoKK
|
| pubmed:issnType |
Print
|
| pubmed:volume |
49
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
800-7
|
| pubmed:dateRevised |
2009-11-11
|
| pubmed:meshHeading |
pubmed-meshheading:9053534-Aged,
pubmed-meshheading:9053534-Anti-Bacterial Agents,
pubmed-meshheading:9053534-Bacteria,
pubmed-meshheading:9053534-Cefoperazone,
pubmed-meshheading:9053534-Drug Therapy, Combination,
pubmed-meshheading:9053534-Female,
pubmed-meshheading:9053534-Humans,
pubmed-meshheading:9053534-Male,
pubmed-meshheading:9053534-Respiratory Tract Infections,
pubmed-meshheading:9053534-Sputum,
pubmed-meshheading:9053534-Sulbactam,
pubmed-meshheading:9053534-beta-Lactamases
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
[Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase].
|
| pubmed:affiliation |
Second Department of Internal Medicine, Nagasaki University School of Medicine.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract
|